MétaCan
Menu
Back to cohort

Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.

2014· article· en· W2604552051 on OpenAlexaff
Irene Braña, Desmond She, Nicole G. Chau, Nhu‐An Pham, Lucia Kim, Shingo Sakashita, Christine Ng, Chang‐Qi Zhu, Albiruni R. Abdul Razak, Eric X. Chen, Lisa Wang, Bayardo Perz-Ordonez, Eric Winquist, Sebastién J. Hotte, Ming‐Sound Tsao, Lillian L. Siu

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsJuravinski Cancer CentreLondon Health Sciences CentreUniversity of TorontoUniversity Health NetworkPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineInternal medicineOncologyPlaceboHead and neck squamous-cell carcinomaPTENCancerGene signatureProgression-free survivalGene expressionHead and neck cancerGeneOverall survivalPathologyPI3K/AKT/mTOR pathwayBiology

Abstract

fetched live from OpenAlex

6041 Background: Dac is a potent, irreversible oral pan-HER tyrosine kinase inhibitor (TKI) with activity demonstrated in a multi-center phase II trial as first-line treatment in pts with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) (NCT01449201; Razak et al. Ann Oncol 2013). No predictive biomarkers currently exist for Dac. Methods: WOO is a single-center, investigator-initiated study which enrolled pts with untreated resectable OCC, ECOG 0-2, and adequate organ functions. Pts were randomized 2:1 to Dac 45 mg or placebo QD for 7-11 days prior to surgery. Pre- and post-treatment (surgical specimen) samples were collected. Study objectives: (1) to evaluate a gene expression signature as a predictor of response to Dac, (2) to assess Ki67 modulation by Dac on paired tumor samples. DGS generation and validation: Using pre- and post-treatment fresh tumor biopsies from 7 pts in the NCT01449201 study as a discovery set, DASL HT12 Illumina gene expression array was performed on RNA. Genes differentially expressed in two groups were identified: pre- vs. post-treatment samples and pts with short vs. long progression-free survival (< 10 weeks vs. > 10 weeks). Genes commonly deregulated in both groups defined the signature DGS. DGS was then applied to pre-treatment samples from the WOO study as a validation, blinded to clinical response. Euclidean distance was used for complete-linkage clustering. Results: 14 pts were enrolled in the WOO study with evaluable samples from 10 pts (Dac/Placebo 8:2; response: yes/no/unknown 4/5/1). In the discovery set, a signature of 47 commonly-deregulated genes was found to be capable of dividing patients as high- or low-expressers pre-treatment. Patients clustered as high-expressers were more likely to be good-responders after treatment (RR = 3.75, 95% C.I. 0.8-21.7). No difference was observed in pre- post-treatment Ki67 between pts on Dac or placebo, nor between responders and non-responders. Conclusions: DGS may identity a subgroup of SCCHN pts more likely to respond to Dac; further validation in other Dac-treated SCCHN pts is ongoing. Clinical trial information: NCT01116843.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.356
Teacher spread0.305 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer Genomics and DiagnosticsFrench-language works237,207